EGFR and anemia (phenotype): Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), can also induce erythrocyte shrinkage and cell membrane phospholipid scrambling [89], and combination of EGFR-TKI and chemotherapy is associated with an even higher incidence of all-grade anemia [90, 91].